Brief: AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study At 63rd American Society Of Hematology Annual Meeting
11/12/2021 18:06
Dec 11 (Reuters) - Allovir Inc ALVR.O :
* ALLOVIR ANNOUNCES POSITIVE PRELIMINARY DATA FROM ONGOING
PHASE 2
POSOLEUCEL MULTI-VIRUS PREVENTION STUDY AT 63RD AMERICAN SOCIETY
OF HEMATOLOGY ANNUAL MEETING
* ALLOVIR - STRENGTH OF PRELIMINARY EFFICACY, SAFETY DATA
SUPPORT
ADVANCEMENT OF POSOLEUCEL INTO PHASE 3 REGISTRATIONAL TRIAL
EXPECTED TO START IN 1H 2022
Source text for Eikon: ID:nBw5P7Hm9a
Further company coverage: ALVR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kalaris Therapeutics
See all newsKalaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
Kalaris Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Kalaris Therapeutics posts smaller-than-expected Q1 net loss
Brief: Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million